Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates dose-dependent brain NAD+ elevation by a novel tricyclic CD38 inhibitor in mice, highlighting a viable strategy for central nervous system disorders.
Cluster of Differentiation 38 (CD38) plays a key role in NAD+ metabolism and calcium signaling, and recent reports highlight therapeutic opportunities for CD38 modulation in central nervous system (CNS) disorders. In this report, we describe the rational design, synthesis, and exploration of structure–activity relationships (SAR) for a novel and brain-penetrant series of tricyclic compounds that form an adduct with ADPR to inhibit CD38 in an uncompetitive manner. Rigidification of the bioactive conformation via covalent tethering of a 6-membered heteroaromatic core to an imidazole warhead served as the key design element that afforded improved biochemical potency against both mouse and human CD38. Incremental property-based optimization of core and linker motifs generated analogues with enhanced unbound brain-to-plasma ratios in mice. These efforts led to the discovery of brain-penetrant CD38 inhibitor 16, which was evaluated in vivo and demonstrated dose-dependent increases of NAD+ measured in mouse brain and lung tissue samples following oral doses ranging from 3 to 100 mg/kg.
No takes yet. Share an insight, caveat, or question.
Hodges et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: